European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

October 28, 2019
Sales and Marketing Astellas, Xospata, leukaemia, pharma

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …

seattle_genetics

Seattle Genetics reports topline phase 3 HER2-Positive Breast Cancer Data

October 25, 2019
Medical Communications

Seattle Genetics, a strong competitor in the breast cancer space, has reported topline results in its phase 3 study evaluating …

top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

It’s another end of the week here at Pharmafile and here we run down our top 10 articles and features …

bbsrc

South West Biosciences to receive £18.5m boost

October 25, 2019

BioSciences in the UK has received a massive boost of £18.5 million awarded from the Biotechnology and Biological Sciences Research …

biogen_logo

Biogen plans Alzheimer’s drug approval after initial research failure

October 25, 2019
Medical Communications

Biogen is planning to seek approval for its experimental drug aducanumab, that could potentially be first to treat Alzheimer’s and …

FlyPharma tackles supply chain challenges and industry best practice at another successful conference

October 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flypharma, pharma

For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges …

pliant

Novartis enters license agreement with Pliant Therapeutics for fibrosis assets

October 24, 2019
Research and Development

Novartis has signed a collaboration and license agreement with Pliant Therapeutics to develop and commercialise preclinical asset PLN-1474 which is …

alkermes

Alkermes to axe 160 jobs in cost-cutting restructure

October 24, 2019
Sales and Marketing

The Irish biopharma company expects to complete most of the job cuts by end of this year and will take …

Novartis receives EC label update approval for Cosentyx in ankylosing spondylitis

October 24, 2019
Research and Development

Novartis has announced that the European Commission has approved a label update for the up-titration of Cosentyx (secukunumab) to 300mg …

nhs_sign

Badly implemented electronic systems putting NHS patients at risk

October 24, 2019
Business Services

A new report has warned that poorly implemented electronic medication systems in the NHS could potentially lead to fatal medication …

gsk_l_rgb

GSK receives wider nod for Zejula as it competes with rival AstraZeneca

October 24, 2019
Research and Development

The US FDA has approved GlaxoSmithKline’s Zejula (niraparib) for the use in advanced ovarian, fallopian tube, or primary peritoneal cancer …

222170359

Damage control: How will pharma manage the health economic impacts of Brexit?

October 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, brexit, health economics and outcomes research, pharma

When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …

vertex-headquarters

FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients

October 23, 2019
Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma

The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …

New study shows Prozac no better than placebo in treating autism

October 23, 2019
Research and Development

A small study has found that the commonly prescribed medication for kids and teenagers with autism is no more effective …

opdivo_1_1

BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

October 23, 2019
Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …

biogen_logo

Biogen aiming for Aducanumab to slow Alzheimer’s progression

October 23, 2019
Research and Development

US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease. …

takeda_world

Takeda acquires investigational coeliac disease therapy

October 23, 2019
Research and Development

Takeda has acquired licensing for a first-in-class investigational coeliac disease therapy CNP-101/TAK-101. The Japanese pharma giant now has the rights …

shutterstock_159488225

Porton Biopharma signs potential $24m deal to push its intranasal anthrax vaccine into Phase 1 trials

October 22, 2019
Manufacturing and Production, Research and Development FDA, Porton Biopharma, anthrax, pharma

Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …

Novo Nordisk opens first Pharmatech branch office in Singapore

October 22, 2019
Manufacturing and Production Novo Nordisk, Singapore, pharma

Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …

teva_copy

Teva offers massive $23 billion to avoid thousands of lawsuits

October 22, 2019
Manufacturing and Production

Israeli drug company Teva has said that it would offer $250 million in cash and a supply of Suboxone, an …

The Gateway to Local Adoption Series

Latest content